

References

S-140

1. Atik A, Hu Y, Yu H, et al. Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy. *BMC Ophthalmol.* 2017;17:140.
2. Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose off verteporfin or half-fluence of laser light for the treatment of CCSC. 2017;37(2):325-333.
3. Fabian I, Stacey A, Papastefanou V, et al. Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma. *Eye.* 2017;31:519-528.
4. Rundle P. Photodynamic therapy for eye cancer. *Biomedicines.* 2017;5:69.
5. Blasi M, Pagliara M, Lanza A, et al. Photodynamic therapy in ocular oncology. 2018;6:17.
6. Tong Y, Zhao KK, Feng D, Biswal M, Zhao PQ, et al. Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: A meta-analysis and systematic review. *Int J Ophthalmol.* 2016;9(7):1028-1037.
7. Zhu Y, Zhang T, Xu G, Zhang T. Anti-vascular endothelial growth factor for choroidal neovascularization in people with pathological myopia. *Cochrane Database Syst Rev.* 2016;12:CD011160.
8. Hayes, Inc. Hayes Health Assessment. *Photodynamic Therapy with Verteporfin (Visudyne) for Choroidal Hemangioma.* Lansdale, PA: Hayes, Inc.; 08/29/2018.
9. Lee JH, Lee WK. One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. *Retina.* 2016;36(5):889-895.
10. Rinaldi M, Semeraro F, Chiosi F, et al. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia. *Graefes Arch Clin Exp Ophthalmol.* 2017;255(3):529-539.
11. National Institute for Health and Care Excellence (NICE). Age-related macular degeneration [NG82]. 2018.
12. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Melanoma: Uveal. Version 2.2021.
13. Rao R, Honavar SG. Retinoblastoma. *Indian J Pediatr.* 2017;84(12):937-944.
14. Mendoza PR, Grossniklaus HE. Therapeutic options for retinoblastoma. *Cancer Control.* 2016;23(2):99-109.
15. Blasi MA, Pagliara MM, Lanza A, et al. Photodynamic therapy in ocular oncology. *Biomedicines.* 2018;6(1):17.

16. Raval V, Tyagi M, Chhablani J, Kaliki S, Reddy R, Das T. Understanding the structural changes following photodynamic and transpupillary thermotherapy for choroidal hemangioma using optical coherence tomography and optical coherence tomography angiography. *Indian J Ophthalmol.* 2019;67(12):2023-2028.
17. Shields CL, Dalvin LA, Lim LS, et al. Circumscribed choroidal hemangioma: Visual outcome in the pre-photodynamic therapy era versus photodynamic therapy era in 458 cases. *Ophthalmol Retina.* 2020;4(1):100-110.